Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
WALTHAM, Mass., Feb. 02, 2016 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the 2016 BIO CEO & Investor Conference in New York City on Monday, February 8, 2016 at 5:00 pm ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.
Investor Contact
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Press Contact
Chris Erdman, MacDougall Biomedical Communications
781-235-3060
[email protected]
